Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BELLUS HEALTH INC. We currently have 16 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
BELLUS HEALTH INC
BELLUS HEALTH INC
BELLUS Health – Taking Stock
15 Aug 16
It has now been nearly two months since BELLUS Health announced that its lead candidate KIACTA™ had not met its primary endpoint in the Phase 3 study completed earlier this year. The shares are 89% down since the news. The company’s recent Q3 release however tells us Shigamab™, a wholly owned programme, has shown further very strong pre-clinical data for sHUS this time in a primate model, and reminds us that BELLUS Health holds interests in a number of third party programmes that have potential we believe not currently reflected in the share price.
Where next for BELLUS Health?
21 Jun 16
The drug development company focused on rare diseases has announced top-line Phase 3 results of KIACTA™ for the treatment of AA amyloidosis. Disappointingly the study did not meet its primary efficacy endpoint (ie shown to have delayed defined adverse events at a P value of 0.05 or less) but was shown to be safe and well tolerated over treatment periods of greater than 4 years. The shares fell 79% on the day to C$0.51.
Countdown to D Day
16 May 16
The drug development company focused on rare diseases last week reported financial and operating results for the quarter ending 31 March. The numbers in themselves contained no surprises. The company made a loss of C$724k vs C$46k in Q1 2015, with the increased loss pertaining largely to a lower level of revenue recognised for accounting purposes in 2016 in relation to the VIVIMIND™ license agreement with FB Health, an increase in general and administrative costs to C$988k from $719k as well as an increase in foreign exchange loss.
Lifesciences Review - Down but not out
21 Mar 16
Stocks in the life sciences industry have struggled to regain their sparkle following the autumn 2015 sell off triggered by Hilary Clinton’s comments on drug pricing with the NASDAQ Biotechnology Index down some 22% since the beginning of the year. Indeed both sides of the presidential race have now targeted pharmaceutical companies with Donald Trump campaigning for price negotiations between drug manufacturers and Medicare
FY2015 results reveal small profit but focus now on vital Q2 KIACTATM data
04 Mar 16
Last week the drug development company focused on rare diseases reported its results for the year ended December 2015. Revenues of C$4m exceeded our C$2.5m expectation. This was due to a higher amount of revenues recognised under the service agreement with the company’s partner on KIACTATM Auven Therapeutics and VIMINDTM license agreement with FB Health. However it should be noted that the cash element of these revenues totaled C$1.3m. On that same basis the company also beat our projections in terms of profitability with a total net profit attributable to shareholders of C$202k compared to a $1.9m loss in FY2014. Year end cash and equivalents of $9.7m were in line with our expectations giving the company some headroom to advance its earlier stage programmes in the event that no deal is struck for KIACTATM this year.
Phase 3 confirmatory trial complete
22 Jan 16
BELLUS Health and its partner Auven therapeutics have announced that the KIACTATM event-driven phase 3 confirmatory study for the treatment of AA amyloidosis, has met its completion target of 120 patient events linked to the deterioration of kidney function. Top line data will take a few months to be compiled after all remaining patients have completed final study visits. The trial has spanned 50 sites worldwide. It is only once this process is complete that the data from the placebo controlled trial will be unblinded and all stakeholders (the company, its shareholders, clinicians and AA amyloidosis sufferers) will know whether the study has met with its primary endpoint which will support global regulatory approvals. The initial results are expected to be released in the second quarter of this year.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
Actual Experience (ACT LN) 2017 – a milestone year for revenue | Bagir Group (BAGR LN) Independent NED appointment to strengthen Board composition | Bioquell (BQE LN) Reassuring pre-close statement | Carador Income Fund (CIFU LN) Q4 dividend increased to 2.75c, 0.5c higher than forecast | FreeAgent (FREE LN) Contract with Royal Bank of Scotland | Halfords Group (HFD LN) Excellent Q3 update, special divi and confidence in FX mitigations | N Brown Group (BWNG LN) Robust peak trading with reversal of drag from older titles | NCC Group (NCC LN) Interims confirm underlying business sound | St Ives (SIV LN) Downgrade | Summit Therapeutics (SUMM LN) Dr David Roblin appointed Chief Operating Officer and R&D President | Wilmington Group (WIL LN) Acquisition – Further scaling of Healthcare
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
N+1 Singer - Morning Song 16-01-2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.